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E-mail address: clelia.dallanoce@unimi.it (C. DallaRacemic exo-epiboxidine 3, endo-epiboxidine 6, and the two unsaturated epiboxidine-related derivatives
7 and 8 were efﬁciently prepared taking advantage of a palladium-catalyzed Stille coupling as the key
step in the reaction sequence. The target compounds were assayed for their binding afﬁnity at neuronal
a4b2 and a7 nicotinic acetylcholine receptors. Epiboxidine 3 behaved as a high afﬁnity a4b2 ligand
(Ki = 0.4 nM) and, interestingly, evidenced a relevant afﬁnity also for the a7 subtype (Ki = 6 nM). Deriva-
tive 7, the closest analogue of 3 in this group, bound with lower afﬁnity at both receptor subtypes
(Ki = 50 nM for a4b2 and Ki = 1.6 lM for a7) evidenced a gain in the a4b2 versus a7 selectivity when
compared with the model compound.
 2008 Elsevier Ltd. All rights reserved.Neuronal nicotinic acetylcholine receptors (nAChRs) make up a
family of pentameric ligand-gated ion channels, which are formed
by combinations of alpha and beta subunits1,2 or exist as homo-
pentamers, in the cases of a7, a8, and a9 receptors, which are
inhibited by a-bungarotoxin.3 To date, nine a (a2–a10) and three
b (b2–b4) isoforms have been characterized, though only a rela-
tively small subset of combinations generates functionally and
physiologically relevant channels.4 Nicotinic receptors are widely
distributed in the brain, where they primarily modulate the release
of other neurotransmitters and, to a lesser extent, mediate synaptic
transmission.5 Neuronal nAChRs, selectively activated by (S)-nico-
tine 1 (Fig. 1), are involved in various processes such as cognition,
learning and memory, cerebral blood ﬂow and metabolism, as well
as an array of pathological conditions such as Alzheimer’s and Par-
kinson’s diseases, mild cognitive impairment (MCI), schizophrenia,
epilepsy, Tourette’s syndrome, anxiety, depression, attention-deﬁ-
cit hyperactivity disorder (ADHD), and nicotine addiction.1,2,6,7
The heteromeric a4b2 receptors, the most abundant subtype in
the mammalian CNS, and the homomeric a7 channels are privi-
leged biological targets in the search for selective nAChR ligands
with therapeutic potential.2,8 As far as the number of nicotinic ago-
nists isolated from natural sources is taken into consideration,9ll rights reserved.
: +39 02 50319326.
noce).()-epibatidine 2 (Fig. 1), a highly toxic alkaloid identiﬁed in the
skin of the Ecuadorian frog Epipedobates tricolor,10 has inspired a
huge amount of research aimed at designing subtype selective nic-
otinic agonists.1,2,9,11,12 Although the pharmacological effects of
()-2 are mediated by a variety of nAChRs,13 which preclude any
therapeutic potential for epibatidine, the analgesic potency,
roughly 100 times higher than that of morphine and 30 times high-
er than that of nicotine, has been attributed to its high afﬁnity for
the a4b2 subtype. Worth mentioning, ()-2 and (+)-2 are charac-
terized by similar afﬁnities for nAChRs and almost identical ED50
values in the mouse tail-ﬂick antinociception assay.13d,14,15
Among the synthetic epibatidine-related compounds, (±)-epib-
oxidine 3 (Fig. 1), in which the 3-methylisoxazolyl moiety has re-
placed the chloropyridinyl ring of the parent derivative, behaved
as a potent a4b2 nicotinic receptor agonist, 10-fold less potent than
epibatidine as antinociceptive agent but about 20-fold less toxic.16
The presence of the 3-methylisoxazole ring was similarly effective
in the structure of (S)-ABT-418 4 (Fig. 1), a nicotine-related a4b2
selective full agonist, which entered Phase I for the treatment of
cognitive dysfunction and was later on discontinued.2,7,17 A further
relevant example of structural analogue of epibatidine is the unsat-
urated derivative (±)-UB-165 5, containing the 9-azabicy-
clo[4.2.1]nonene skeleton, a high afﬁnity nicotinic partial agonist
which allowed to clarify the involvement of the a4b2 subtype in
modulating dopamine release from rat striatal synaptosomes.18,19
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Figure 1. Structures of model and target compounds in this study.
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idine, that is, at a7 nAChRs, a subtype on which, to the best of our
knowledge, it was never assayed. To this end, we thought about a
ﬂexible synthesis of (±)-3 allowing also the preparation of unsatu-
rated structurally related derivatives. Accordingly, we describe a
novel synthetic route to epiboxidine 3 (exo-isomer), its epimer
endo-epiboxidine 6, and the two unprecedented dehydro-ana-
logues of epiboxidine 7 and 8. The target chiral compounds, whose
structures are reported in Figure 1, were prepared and tested as
racemates.
As illustrated in the upper part of Scheme 1, the known prepa-
rations of 3 took advantage of the reaction of 7-azabicy-
clo[2.2.1]heptane-2,7-dicarboxylic acid diesters 9a and 9b with
the dianion of acetone oxime, followed by acidic treatment of
intermediates 10a and 10b.16,20 As an alternative approach, we
planned to make use of a Stille palladium-catalyzed cross-coupling
reaction,21 which involved the coupling of enoltriﬂate 11 with 3-
methyl-5-tributylstannylisoxazole 12, as depicted in the lower
part of Scheme 1.
Initially, we made use of a known procedure to prepare 7-tert-
butoxycarbonyl-7-azabicyclo[2.2.1]heptan-2-one 16, a key inter-
mediate in one of the syntheses of (±)-epibatidine.22 The ﬁrst step
of the sequence, a [4+2] cycloaddition of N-Boc-pyrrole 13, used in
large excess, to methyl 3-bromopropiolate 14, was performed un-
der microwave heating (Scheme 2).23 These experimental condi-
tions allowed reduction of the reaction time (from 30 to 1.5 h)
and improvement of the yield of the Diels-Alder adduct 15 (from
60% to 85%). Subsequently, we prepared the known triﬂuorometh-N
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Scheme 1. (A) Key steps of the known synthetic strategy to epiboxidine 3. (B)
Retrosynthesis of 3 based on a Stille coupling reaction.anesulfonate 1124 in 62% isolated yield by treatment of ketone 16
with LDA in THF at 78 C25 followed by reaction with N-(5-
chloro-2-pyridyl)bis(triﬂuoromethanesulfonimide)26 (Scheme 2).
3-Methyl-5-tributylstannylisoxazole 12 was obtained through the
previously described 1,3-dipolar cycloaddition of tributylethynyl-
tin 17 to acetonitrile oxide.27 As a modiﬁcation of the known pro-
cedure, we chose to isolate the stable precursor of the 1,3-dipole,
that is, the acetohydroximoyl chloride 18, which in turn was syn-
thesized by reacting acetaldoxime with benzyltrimethylammoni-
um tetrachloroiodate (BTMA ICl4).28,29 In this way, the target
tributylstannylisoxazole 12 was prepared in acceptable yields
(45–50%).
The Stille cross-coupling reaction of triﬂate 11 to isoxazole 12,
performed in the presence of the Tris(dibenzylideneacetone)dipal-
ladium(0)-chloroform adduct, triphenylphosphine, and anhydrous
ZnCl2, produced the 7-azabicyclo[2.2.1]hept-2-ene derivative 19 in
90% yield (Scheme 3).30 Removal of the N-Boc protection of 19with
a 4 N solution of HCl in dioxane afforded the secondary amine 7,
which was converted into the corresponding N-methyl derivative
8 by a standard reaction with formaldehyde followed by reduction
NO
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Scheme 3. (a) [Pd2(dba)3]CHCl3, PPh3, 12, anhydrous ZnCl2/THF, 78 C to rt; (b) 4 N HCl/dioxane, rt; (c) aq Na2CO3; (d) HCHO (37%, aq), NaBH3CN/CH3CN; (e) H2, 10% Pd/C,
CH3OH; (f) tert-BuOK/tert-BuOH, reﬂux, 16 h, ﬂash chromatography; (g) C4H4O4, CH3OH.
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hydrogenation of the carbon–carbon double bond of 19 over 10%
Pd/C allowed the isolation of N-Boc-endo-epiboxidine 20 as the
sole isomer in 87% yield.31 Epimerization of 20 using potassium
tert-butoxide in reﬂuxing tert-butyl alcohol22,31 provided the de-
sired N-Boc-exo-epiboxidine 21 in 82% yield. The two epiboxidine
epimers endo-6 and exo-3 were isolated as crystalline hydrochlo-
rides following acidic treatment of the corresponding N-Boc pro-
tected endo-20 and exo-21 precursors, respectively (Scheme 3).
Speciﬁcally, the physical and spectroscopic features of 3 hydro-
chloride16,32 matched those of the known compound, now com-
mercially available from Sigma. Since the hydrochlorides of 7 and
8 were amorphous salts, the free bases were reacted with a solu-
tion of fumaric acid in methanol to give rise to the corresponding
1:1 fumarates (Scheme 3).
The target racemic compounds 3, 6, 7, and 8 were assayed for
binding afﬁnity at rat a4b2 and a7 nAChR subtypes, using [3H]epi-
batidine and [125I]a-bungarotoxin as radioligands, respectively.
The Ki values, calculated from the competition curves of three
separate experiments by means of the LIGAND program,33 are col-
lected in Table 1. The corresponding values reported for (±)-epi-
batidine 2, (S)-4 (ABT-418), and (±)-5 (UB-165) have been
included for comparison.
The data found for epiboxidine 3 conﬁrm its very high afﬁnity
(Ki = 0.4 nM) for a4b2 nAChRs, which complements the results
known from the literature (Ki = 0.6 nM,16 Ki = 1.33 nM,34 and
Ki = 0.46 nM35). A comparison between 2 and 3 evidences about a
10-fold higher afﬁnity of 2 at the a4b2 receptors (Ki valuesTable 1
Afﬁnity of (±)-epibatidine 2, ABT-418 (S)-4, UB-165 5, and derivatives 3, 6, 7, and 8 for
native a4b2 and a7 nAChR subtypes present in rat cortical membranes, labeled by
[3H]epibatidine and [125I]a-bungarotoxin
Entry a4b2 [3H]-Epi Ki (nM) a7 [125I]a-BgTx Ki (nM)
(±)-2 0.035a 10.2a
(S)-4 20.0b 1200b
(±)-5 0.27c 2790c
(±)-3 0.40 (57) 6.0 (47)
(±)-6 70 (49) 230 (51)
(±)-7 50 (23) 1600 (63)
(±)-8 514 (34) 394 (44)
The numbers in brackets refer to the % coefﬁcient of variation.
a Ref. 40, [3H]nicotine was used as radioligand for a4b2 receptors.
b Ref. 36.
c Ref. 19, [3H]nicotine was used as radioligand for a4b2 receptors.0.035 nM for 2 and 0.4 nM for 3) combined with a lower afﬁnity
at a7 receptors (Ki values 10.2 nM for 2 and 6.0 nM for 3). As a con-
sequence, a meaningful difference in the a4b2 versus a7 selectivity
ratio (290 for 2 and 15 for 3) characterizes the two structural ana-
logues. An intermediate selectivity has been recently found for the
3-methylisoxazolyl nicotine-related derivative ABT-418 (S)-4.36 If
the data on epiboxidine 3 are taken into account, the binding afﬁn-
ity of (S)-4 at the a7 subtype (Ki = 1.2 lM) is negatively affected
more than at the a4b2 receptors (Ki = 20 nM), thus bringing about
an a4b2 versus a7 selectivity ratio of 60.
In terms of binding afﬁnity, UB-165 5, the semirigid homologue
of epibatidine, showed a considerable degree of discrimination be-
tween the two neuronal nAChRs under study, the a4b2 versus a7
selectivity being higher than 10,000, due to a partially conserved
afﬁnity at the a4b2 subtype (Ki = 0.27 nM) coupled with a sizeable
loss of afﬁnity at the a7 subtype (Ki = 2.8 lM).19 Also derivative 7,
the unsaturated analogue of epiboxidine, was characterized by a
marked drop of the afﬁnity at the a7 subtype (Ki = 1.6 lM) when
compared to the parent compound. However, the presence of the
double bond in 7 caused a reduction of the afﬁnity even at the
a4b2 subtype (Ki = 50 nM). As a consequence, only a minor
improvement of the a4b2 versus a7 selectivity (from 15 for 3 to
32 for 7) was attained. Worth noting, in terms of afﬁnity proﬁle
at the two studied nAChRs, the results on racemic 7 are quite com-
parable with those obtained in the same experimental conditions
for the pure isomer ABT-418.36
At variance with the secondary amine 7, the corresponding N-
methyl derivative 8 was characterized as a low afﬁnity unselective
nicotinic ligand (Ki = 0.51 lM at a4b2 and 0.39 lM at a7). A similar
lack of selectivity was evidenced by endo-epiboxidine 6, which, in
comparison with the exo-isomer 3, retained a non negligible afﬁn-
ity at both a4b2 (Ki = 70 nM) and a7 (Ki = 0.23 lM) nAChR
subtypes. The same trend was reported at the a4b2 subtype for
(±)-endo-epibatidine,13d which exhibited a drastic reduction of
afﬁnity when compared to (±)-exo-epibatidine (Ki values 7.6 and
0.035 nM, respectively),37 coupled with the loss of the antinocicep-
tive activity in the tail-ﬂick test.14
In summary, we utilized a Pd-catalyzed Stille coupling reaction
as the pivotal step to prepare the two epiboxidine epimers and two
unsaturated epiboxidine-related analogues. We assessed the four
compounds for binding afﬁnity at a4b2 and a7, the two major neu-
ronal nicotinic receptor subtypes. Noteworthy, (±)-exo-epiboxidine
3 displayed a very high afﬁnity at both nAChRs, whereas in its ana-
logue 7 the presence of the double bond caused a loss of afﬁnity at
both subtypes together with a higher degree of a4b2 versus a7
4654 L. Rizzi et al. / Bioorg. Med. Chem. Lett. 18 (2008) 4651–4654selectivity. We will broaden the study on this set of compounds by
enriching the number of unsaturated analogues and preparing the
individual isomers of (±)-3 and (±)-7. The pharmacological results
will be further analyzed in the light of recently developed molecu-
lar models for the two investigated receptor subtypes.38,39
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